Maria T. Cedena

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Journal: Journal for immunotherapy of cancer

Published: February 25, 2026

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Journal: HemaSphere

Published: December 23, 2025

Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis.

Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis.

Journal: Biomedicines

Published: October 16, 2025

Immune biomarkers of increased infection risk in multiple myeloma.

Immune biomarkers of increased infection risk in multiple myeloma.

Journal: Blood

Published: September 22, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances

Published: September 18, 2025

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 01, 2024

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure.

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure.

Journal: Life (Basel, Switzerland)

Published: May 31, 2023

Impact of IPSS-M implementation in real-life clinical practice.

Impact of IPSS-M implementation in real-life clinical practice.

Journal: Frontiers in oncology

Published: April 02, 2023

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Journal: Blood

Published: December 28, 2022

Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD.

Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD.

Journal: Therapeutic advances in hematology

Published: January 16, 2022

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 14, 2022

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.

Journal: Journal of hematology & oncology

Published: June 29, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026